Recent Stock Changes
Several hedge funds have adjusted their AstraZeneca holdings recently:
- GHP Investment Advisors bought $26,000 worth in Q2.
- Able Wealth Management invested $27,000 in Q4.
- Pathway Financial Advisers acquired $29,000 worth in Q1.
- RFP Financial Group increased its stake by 56.3% in Q1, now owning shares worth $33,000.
- CANADA LIFE ASSURANCE raised its stake by 40.6% in Q1, now valued at $34,000.
Overall, hedge funds own 20.35% of AstraZeneca.
AstraZeneca Stock Update
On Thursday, AstraZeneca’s stock (NASDAQ: AZN) opened at $77.51. Key stats include:
- Market cap: $240.31 billion
- P/E ratio: 37.99
- 12-month range: $60.47 – $87.68
Quarterly Earnings
AstraZeneca’s latest quarterly earnings posted on July 25 showed an EPS of $0.99, beating estimates. Revenue was $12.45 billion, a 9.1% increase from the previous year, but below the forecast of $12.62 billion.
Dividend Info
The company paid a semi-annual dividend of $0.49 on September 9, with a yield of 1.8% and a payout ratio of 48.04%.
Analyst Ratings
Analysts have mixed views on AstraZeneca:
- TD Cowen raised the target price to $95 (buy rating).
- Erste Group upgraded to buy.
- Deutsche Bank downgraded to sell.
- Overall, seven analysts gave buy ratings, and two rated it a strong buy.
About AstraZeneca
AstraZeneca PLC focuses on developing and distributing prescription drugs, including treatments for oncology and cardiovascular conditions.
Featured Articles
- Five stocks we prefer over AstraZeneca
- 3 Healthcare Dividend Stocks to Consider
- Future Medical Devices: Two Strong Buys
Stay updated on AstraZeneca: Check out HoldingsChannel.com for the latest insights.
Receive Daily Updates: Enter your email for a summary of AstraZeneca news with MarketBeat.com’s FREE email newsletter.
`
